Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a report issued on Monday,Benzinga reports. They currently have a $58.00 price target on the stock. BTIG Research’s price target would indicate a potential upside of 71.29% from the company’s current price.

Several other analysts also recently commented on the stock. Lifesci Capital raised shares of Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada restated an “underperform” rating and set a $24.00 target price on shares of Sionna Therapeutics in a research report on Monday, December 1st. Citizens Jmp initiated coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price objective for the company. Citigroup started coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They issued an “outperform” rating on the stock. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.63.

Sionna Therapeutics Stock Down 7.3%

SION traded down $2.68 during trading hours on Monday, reaching $33.86. 91,702 shares of the company’s stock traded hands, compared to its average volume of 279,310. The firm has a market capitalization of $1.51 billion and a PE ratio of -6.95. The firm has a 50-day moving average price of $39.78 and a 200 day moving average price of $35.13. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter.

Insider Transactions at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 33,356 shares of the stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc sold 33,356 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the transaction, the director directly owned 3,561,655 shares in the company, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 382,368 shares of company stock valued at $15,898,607. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently bought and sold shares of the business. Braidwell LP purchased a new position in shares of Sionna Therapeutics in the second quarter valued at $18,770,000. Eventide Asset Management LLC acquired a new position in Sionna Therapeutics during the 4th quarter worth approximately $26,290,000. Vanguard Group Inc. increased its position in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after acquiring an additional 512,803 shares during the last quarter. State Street Corp boosted its stake in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after acquiring an additional 453,196 shares during the last quarter. Finally, Viking Global Investors LP increased its holdings in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after acquiring an additional 242,427 shares during the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.